Related Experiment Videos
Diminution of circulating polymorphonuclear leucocytes by administration of a monoclonal antibody reacting with
Abstract:
The monoclonal antibody 3A35 which binds mouse polymorphonuclear leucocytes (PMN) and monocytes was injected intravenously (i.v.) into normal mice. A great diminution of circulating PMN was observed. The percentage of PMN passed through a minimum (2.5%) 20 min after antibody injection and returned to normal value (18.3%) within 24 h. After repeated daily injections, the ability of the antibody to induce granulopenia attenuated. Moreover, mice bearing the 3A35-producing hybridoma as an ascitic tumor had a normal percentage of blood PMN and a normal granulopoiesis as judged from bone marrow cytological examination. Thus, the monoclonal antibody produced a transitory diminution of PMN but could not induce a lasting granulopenia.
Insights
Monoclonal antibody 3A35 temporarily reduced circulating polymorphonuclear leucocytes (PMN) in mice. However, it did not cause lasting granulopenia, even with repeated injections or tumor presence.
Area of Science:
- Immunology
- Hematology
Background:
- Monoclonal antibodies are crucial tools in immunology research.
- Understanding the in vivo effects of antibodies on immune cells is essential.
Purpose of the Study:
- To investigate the effects of monoclonal antibody 3A35 on circulating polymorphonuclear leucocytes (PMN) in mice.
- To determine if repeated administration or tumor burden alters the antibody's impact on granulopoiesis.
Main Methods:
- Intravenous injection of monoclonal antibody 3A35 into normal mice.
- Monitoring of circulating PMN percentages over time.
- Assessment of bone marrow cytology in mice bearing antibody-producing hybridoma tumors.
Main Results:
- A significant, transient decrease in circulating PMN was observed post-injection.
- PMN levels returned to normal within 24 hours.
- Repeated injections and hybridoma tumor presence did not lead to sustained granulopenia or affect bone marrow granulopoiesis.
Conclusions:
- Monoclonal antibody 3A35 induces a temporary reduction in circulating PMN.
- The antibody does not cause long-term granulopenia or disrupt normal granulopoiesis in mice.